WeChat· 迪福润丝生物·· 2026-08-20PickScore73
FDA Grants Accelerated Approval to Replimune's Tudriqev with PD-1 Inhibitor for Advanced Melanoma
In brief
On August 6, 2026, the FDA granted accelerated approval to Replimune's oncolytic virus therapy Tudriqev in combination with a PD-1 inhibitor for patients with PD-1-resistant advanced melanoma. It is the first approved oncolytic virus combination therapy worldwide and the first oncolytic virus approval by the FDA in 11 years.
Why it matters
First FDA-approved oncolytic virus combination therapy and first oncolytic virus approval in 11 years.
Source: WeChat · mp.weixin.qq.com